Transgenic Plasmodium falciparum expressing luciferase offers an attractive bioluminescence-based assay platform for the investigation of the pharmacological properties of anti-malarial drugs. Here a side-by-side comparison of bioluminescence and fluorescence-based assays, utilizing a luciferase reporter cassette that confers a strong temporal pattern of luciferase expression during the S-phase of intraerythrocytic development, is reported

Devine, O

Hasenkamp, S

Horrocks, P

Roye, R

Sidaway, A

Malaria Journal

PubMed

Name not available

Evaluation of bioluminescence-based assays of anti-malarial drug activity

Abstract
          
            Background
            Transgenic Plasmodium falciparum expressing luciferase offers an attractive bioluminescence-based assay platform for the investigation of the pharmacological properties of anti-malarial drugs. Here a side-by-side comparison of bioluminescence and fluorescence-based assays, utilizing a luciferase reporter cassette that confers a strong temporal pattern of luciferase expression during the S-phase of intraerythrocytic development, is reported.
          
          
            Methods
            Key assay parameters for a range of commercially available luminogenic substrates are determined and compared to those measured using a Malaria Sybr Green I fluorescence assay. In addition, the short-term temporal effects of anti-malarial compounds are evaluated using both bioluminescent and fluorescent assay platforms.
          
          
            Results
            The Z’, % coefficient of variation and 50% inhibition concentrations are essentially the same for bioluminescent and fluorescent assays in transgenic parasites generated in both chloroquine-sensitive and -resistant genetic backgrounds. Bioluminescent assays, irrespective of the luminogenic agent employed, do, however, offer significantly enhanced signal-to-noise ratios. Moreover, the bioluminescent assay is more dynamic in terms of determining temporal effects immediately following drug perturbation.
          
          
            Conclusion
            This study suggests that opportunities for bioluminescence-based assays lie not in the measurement of 50% inhibition concentrations, where the cheaper fluorescence assay performs excellently and is not restricted by the need to genetically modify the parasite clone under investigation. Instead, assays that use the dynamic response of the luciferase reporter for semi-automated screening of additional pharmacological properties, such as relative rate-of-kill and lethal dose estimation, are a more attractive development opportunity.
          </jats:sec

Sandra Hasenkamp

Adam Sidaway

Oliver Devine

Richard Roye

Paul Horrocks

Crossref

Springer - Publisher Connector

al: Chemical genetics of Plasmodium falciparum.

An improved single-step lysis protocol to measure luciferase bioluminescence in Plasmodium falciparum.

Analysis of the molecular mechanisms governing the stage-specific expression of a prototypical housekeeping gene during intraerythrocytic development of P.

Chulay JD: Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother

CJ: Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites.

D: Challenges in antimalarial drug discovery. Future Med Chem

Fidock DA: Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nat Methods

Fidock DA: Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches.

Fidock DA: Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmissionblocking activity by methylene blue.

Gamo FJ: P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS One

GarciaBustos JF: Thousands of chemical starting points for antimalarial lead identification. Nature

Greenbaum DC: Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay. Antimicrob Agents Chemother

Herreros E: Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence “transmission blocking” assay. PLoS One

High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother

Mehlotra RK: Expanding the antimalarial drug arsenal-now, but how? Pharmaceuticals (Basel)

Mendoza-Losana A: A new molecular approach for cidal vs static antimalarial determination by quantifying mRNA levels. Mol Biochem Parasitol

Plasmodium falciparum: development of a transgenic line for screening antimalarials using firefly luciferase as the reporter. Exp Parasitol

Roepe PD: Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob Agents Chemother

Roepe PD: Plasmodium falciparum resistance to cytocidal versus cytostatic effects of chloroquine. Mol Biochem Parasitol

Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother

Validating a firefly luciferase-based high-throughput screening assay for antimalarial drug discovery. Assay Drug Dev Technol

Vanderberg JP: Synchronization of Plasmodium falciparum erythrocytic stages in culture.

Winzeler EA: In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA

http://www.malariajournal.com/content/12/1/58

Evaluation of bioluminescence-based assays of anti-malarial drug activity

Abstract

Similar works

Full text

Available Versions

Name not available

Crossref

Springer - Publisher Connector